Healthcare Economics & Policy

An undocumented immigrant living in Brooklyn, N.Y., was deported to his home country last Wednesday after ICE officials ignored attorneys’ requests to keep him in the U.S. for much-needed medical treatment, WNYC reported.

Ranna Parekh, MD, MPH, has been named by the American College of Cardiology as its first director of diversity and inclusion, according to a statement issued by the College May 23.

Cardiologist Andrea M. Russo, MD, took the reins of the Heart Rhythm Society as president this month after an induction ceremony at the organization’s annual meeting in San Francisco.

Body mass index, systolic blood pressure and smoking behaviors mediate the effects of education on cardiovascular health, according to a recent study in The BMJ.

A federal judge on May 15 ruled the FDA acted illegally more than a year and a half ago when it allowed e-cigarette products geared toward kids and teens to remain on the market prior to and during the agency’s approval process.

A new rule issued by HHS under the Trump administration allows physicians, hospitals and insurers to refuse care to certain patients on grounds of religious beliefs—something a New York Times columnist says could lead to “chaos in healthcare."

Earning approval to use a new cardiovascular drug in the clinical setting can cost 100+ times the average of bringing other medications to market.  

A former Kentucky cardiologist received five years of prison time May 2 after allegedly performing numerous unnecessary heart procedures as part of a healthcare fraud scheme.

The American Heart Association, alongside the American Cancer Society Cancer Action Network, American Lung Association, American Academy of Pediatrics and Tobacco-Free Kids, is throwing its support behind federal efforts to raise the tobacco sale age to 21 nationwide.

Heart disease might be the leading cause of death in the United States, but, according to a recent report, it’s also one of the least searched-for diseases on the internet.

The FDA has expanded Praluent’s (alirocumab) regulatory approval to reflect the reduced risk of heart attack, stroke and unstable angina evidenced in 2018’s ODYSSEY OUTCOMES trial—a move announced the same day drugmaker Sanofi released its first-quarter earnings, which were lower than expected.

CMS saw an influx of public commentary after it first published a draft of recommendations for revising the United States’ national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) more than a month ago. Now that the 30-day comment period is over, the agency has a decision to make.